SLU Researchers to Test Gammaglobulin for Alzheimer’s Disease
St. Louis University
This fall, researchers from Saint Louis University will begin testing an intriguing new approach to slowing down the progression of Alzheimer’s Disease using Intravenous Immune Globulin (IGIV), also known as gammaglobulin. IGIV is currently used to treat primary immunodeficiency disorders but is not currently approved for treating AD, which is one of the leading causes of dementia in the elderly.
Investigators will examine whether IGIV, which is made from the blood of several thousand healthy adults and contains naturally occurring human anti-amyloid antibodies, will defend the brain of AD patients against the damaging effects of beta amyloid, the protein that forms the core of plaques in the brain, with the hope that giving IGIV to patients with mild to moderate Alzheimer’s may potentially slow the rate of progression of the disease.
Via SLU Researchers to Test Gammaglobulin for Alzheimer’s Disease
Posted on November 23, 2009 | No Comments | Category: Alzheimer's, Caregiving, Dementia | Tags: Autism, Caregiving, Dementia, drug, FDA
Comments
Leave a Reply
